For how we live.
In 143 people with poorly controlled type 1 diabetes, a system that prompts injections through glucose-sensor alerts was non-inferior to standard monitoring — and acting on the alerts drove the benefit.
In 4,299 people with type 1 diabetes and 17,196 matched controls, the death rate was 131 vs 35 per 100,000 person-years. The excess risk was far larger in women, though absolute mortality was higher in men.
Thirteen years on, the independent DiAPREV-IT trial still shows no overall effect from GAD-alum. A 27-child genetic subgroup saw onset delayed — but the other subgroup got worse.
In the DIABIL-2 trial, low-dose interleukin-2 hit its immune target in people newly diagnosed with type 1 diabetes, yet failed to preserve insulin-producing cells at one year.
Both raise blood sugar, but for opposite reasons. Type 1 is an autoimmune loss of insulin; type 2 is the body resisting the insulin it makes. Type 2 accounts for 90 to 95 percent of cases.
Danger lies at both ends. Below 70 mg/dL blood sugar is too low; sustained highs can tip into ketoacidosis above 200 mg/dL or a hyperosmolar crisis above 600. Both extremes are medical emergencies.
A closed-loop system links a glucose sensor to an insulin pump so software doses automatically. In the pivotal 6-month trial it raised time in target range by 11 points over a standard pump — a bounded gain, not a cure.
A 740,744-child natural experiment tested a decade-old hypothesis that rotavirus vaccine might prevent type 1 diabetes. It found no protective effect — and no evidence of harm either.
Emulating a trial inside Veterans Health Administration records, researchers estimated adjusted mortality risk ratios of 0.90 to 0.84 for starting continuous glucose monitoring in older-onset type 1 diabetes.
Gene-edited islet cells implanted in a person's forearm are still functioning more than a year later. It is a single case report, and will need many more patients to mean anything.
PHARMAC's October 2024 decision left one brand's sensors unfunded, forcing a device switch. A single-centre audit of 79 children found HbA1c fell slightly — and cannot say the switch caused it.
A 230-patient survey from one US diabetes center found symptomatic hypoglycemia more than twice as common with adjunctive tirzepatide as with semaglutide, though GI side effects were similar between the two.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
The CHMP's November meeting produced ten positive opinions. Two of them — teplizumab and a Telethon-sponsored gene therapy — address conditions the EU has had no authorised treatment for.
The 27 recommendations cover monitoring, diet and medication for type 1, type 2 and gestational diabetes. WHO had guidance on diabetes and guidance on pregnancy, but never on the two together.